The impact of diet and micronutrient supplements on the expression of neuroendocrine markers in murine Lady transgenic prostate

Prostate

Volumn 68, Issue 4, 2008, Pages 345-353

  Palmer, Jodie ^a,e   Venkateswaran, Vasundara ^b   Fleshner, Neil E ^c   Klotz, Laurence H ^b   Cox, Michael E ^a,d  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

CgA; Dietary; Neuroendocrine; Prostate cancer; Transgenic

Indexed keywords

BOMBESIN; CALCITONIN; CHROMOGRANIN A; NEURON SPECIFIC ENOLASE; NEUROTENSIN; PARATHYROID HORMONE RELATED PROTEIN; SEROTONIN; TRACE ELEMENT;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL DIFFERENTIATION; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE SEVERITY; IMMUNOHISTOCHEMISTRY; LIPID DIET; MALE; METASTASIS; NEUROENDOCRINE SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROTEIN EXPRESSION; TRANSGENIC MOUSE; TUMOR VOLUME;

ADENOCARCINOMA; ANIMAL FEED; ANIMALS; BIOLOGICAL MARKERS; BOMBESIN; CARCINOMA, NEUROENDOCRINE; CHROMOGRANIN A; DIETARY FATS; DISEASE MODELS, ANIMAL; MALE; MICE; MICE, INBRED STRAINS; MICE, TRANSGENIC; MICRONUTRIENTS; NEUROTENSIN; PARATHYROID HORMONE-RELATED PROTEIN; PHOSPHOPYRUVATE HYDRATASE; PROSTATE; PROSTATIC NEOPLASMS; SEROTONIN;

EID: 40349106021     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20692     Document Type: Article

References (52)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57(1):43-66.
2. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, Morrison H, Sonawane B, Shifflett T, Waters DJ, Timms B. Human prostate cancer risk factors. Cancer 2004;101 (10 Suppl): 2371-2490.
3. Rubin MA, DeMarzo AM. Molecular genetics of human prostate cancer. Mod Pathol 2004;17(3):380-388.
4. Fleshner N, Bagnell PS, Klotz L, Venkateswaran V. Dietary fat and prostate cancer. J Urol 2004;171(2 Pt 2):S19-S24.
5. Fleshner NE. Vitamin E and prostate cancer. Urol Clin North Am 2002;29(1):107-113, ix.
6. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults - The Evidence Report. National Institutes of Health. Obes Res 1998;6 (Suppl 2): 51S-209S.
7. Fleshner N, Al Azab R. Prostate cancer: Chemoprevention update 2005. Can J Urol 2005;12 (Suppl 2):2-4.
8. Fleshner N, Fair WR, Huryk R, Heston WD. Vitamin E inhibits the high-fat diet promoted growth of established human prostate LNCaP tumors in nude mice. J Urol 1999;161(5):1651-1654.
9. Fleshner NE, Kucuk O. Antioxidant dietary supplements: Rationale and current status as chemopreventive agents for prostate cancer. Urology 2001;57 (4 Suppl 1):90-94.
10. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM, Greenberg NM. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996;56(18):4096-4102.
11. Masumori N, Thomas TZ, Chaurand P, Case T, Paul M, Kasper S, Caprioli RM, Tsukamoto T, Shappell SB, Matusik RJ. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res 2001;61(5):2239-2249.
12. Amorino GP, Parsons SJ. Neuroendocrine cells in prostate cancer. Crit Rev Eukaryot Gene Expr 2004;14(4):287-300.
13. Krijnen JL, Bogdanowicz JF, Seldenrijk CA, Mulder PG, van der Kwast TH. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol 1997; 158(1):171-174.
14. di Sant'Agnese PA. Neuroendocrine differentiation in human prostatic carcinoma. Hum Pathol 1992;23(3):287-296.
15. Guate JL, Escaf S, Menendez CL, del Valle M, Vega JA. Neuroendocrine cells in benign prostatic hyperplasia and prostatic carcinoma: Effect of hormonal treatment. Urol Int 1997;59(3):149-153.
16. Bonkhoff H, Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: A stem cell model. Prostate 1996;28(2):98-106.
17. Bonkhoff H, Wernert N, Dhom G, Remberger K. Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate. Prostate 1991;19(2): 91-98.
18. Abrahamsson PA. Neuroendocrine differentiation and hormone-refractory prostate cancer. Prostate Suppl 1996;6:3-8.
19. Pruneri G, Galli S, Rossi RS, Roncalli M, Coggi G, Ferrari A, Simonato A, Siccardi AG, Carboni N, Buffa R. Chromogranin A and B and secretogranin II in prostatic adenocarcinomas: Neuroendocrine expression in patients untreated and treated with androgen deprivation therapy. Prostate 1998;34(2):113-120.
20. Wafa LA, Palmer J, Fazli L, Hurtado-Coll A, Bell RH, Nelson CC, Gleave ME, Cox ME, Rennie PS. Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors. Hum Pathol 2007;38(1):161-170.
21. Dauge MC, Delmas V. A.P.U.D. type endocrine tumour of the prostate. Incidence and prognosis in association with adenocarcinoma. Prog Clin Biol Res 1987;243A:529-531.
22. Cohen RJ, Glezerson G, Haffejee Z. Neuro-endocrine cells - a new prognostic parameter in prostate cancer. Br J Urol 1991; 68(3):258-262.
23. Tarle M, Frkovic-Grazio S, Kraljic I, Kovacic K. A more objective staging of advanced prostate cancer-routine recognition of malignant endocrine structures: The assessment of serum TPS, PSA, and NSE values. Prostate 1994;24(3):143-148.
24. Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF Jr. Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer 1997;80(11):2109-2119.
25. Bostwick DG, Qian J, Pacelli A, Zincke H, Blute M, Bergstralh EJ, Slezak JM, Cheng L. Neuroendocrine expression in node positive prostate cancer: Correlation with systemic progression and patient survival. J Urol 2002;168(3):1204-1211.
26. Hvamstad T, Jordal A, Hekmat N, Paus E, Fossa SD. Neuroendocrine serum tumour markers in hormone-resistant prostate cancer. Eur Urol 2003;44(2):215-221.
27. Cussenot O, Villette JM, Cochand-Priollet B, Berthon P. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors. Prostate Suppl 1998;8:43-51.
28. Deftos LJ, Abrahamsson PA. Granins and prostate cancer. Urology 1998;51 (5A Suppl):141-145.
29. Deftos LJ, Nakada S, Burton DW, di Sant'Agnese PA, Cockett AT, Abrahamsson PA. Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. Urology 1996;48(1): 58-62.
30. Feldman SA, Eiden LE. The chromogranins: Their roles in secretion from neuroendocrine cells and as markers for neuroendocrine neoplasia. Endocr Pathol 2003;14(1):3-23.
31. Lee LF, Guan J, Qiu Y, Kung HJ. Neuropeptide-induced androgen independence in prostate cancer cells: Roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Mol Cell Biol 2001;21(24):8385-8397.
32. Elek J, Pinzon W, Park KH, Narayanan R. Relevant genomics of neurotensin receptor in cancer. Anticancer Res 2000;20(1A): 53-58.
33. Motellon JL, Javort Jimenez F, de Miguel F, Jaras MJ, Diaz A, Hurtado J, Esbrit P. Parathyroid hormone-related protein, parathyroid hormone, and vitamin D in hypercalcemia of malignancy. Clin Chim Acta 2000;290(2):189-197.
34. Boabaid F, Berry JE, Koh AJ, Somerman MJ, McCcauley LK. The role of parathyroid hormone-related protein in the regulation of osteoclastogenesis by cementoblasts. J Periodontol 2004;75(9): 1247-1254.
35. Matsuzaki K, Udagawa N, Takahashi N, Yamaguchi K, Yasuda H, Shima N, Morinaga T, Toyama Y, Yabe Y, Higashio K, Suda T, Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Commun 1998;246(1):199-204.
36. Evangelou AI, Winter SF, Huss WJ, Bok RA, Greenberg NM. Steroid hormones, polypeptide growth factors, hormone refractory prostate cancer, and the neuroendocrine phenotype. J Cell Biochem 2004;91(4):671-683.
37. Deeble PD, Murphy DJ, Parsons SJ, Cox ME. Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol 2001;21(24):8471-8482.
38. Farini D, Puglianiello A, Mammi C, Siracusa G, Moretti C. Dual effect of pituitary adenylate cyclase activating polypeptide on prostate tumor LNCaP cells: Short- and long-term exposure affect proliferation and neuroendocrine differentiation. Endocrinology 2003;144(4):1631-1643.
39. Deeble PD, Cox ME, Frierson HF Jr, Sikes RA, Palmer JB, Davidson RJ, Casarez EV, Amorino GP, Parsons SJ. Androgen-independent growth and tumorigenesis of prostate cancer cells are enhanced by the presence of PKA-differentiated neuroendocrine cells. Cancer Res 2007;67(8):3663-3672.
40. Venkateswaran V, Fleshner NE, Sugar LM, Klotz LH. Antioxidants block prostate cancer in lady transgenic mice. Cancer Res 2004;64(16):5891-5896.
41. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995;92(8):3439-3443.
42. Venkateswaran V, Fleshner NE, Klotz LH. Synergistic effect of vitamin E and selenium in human prostate cancer cell lines. Prostate Cancer Prostatic Dis 2004;7(1):54-56.
43. Venkateswaran V, Fleshner NE, Klotz LH. Modulation of cell proliferation and cell cycle regulators by vitamin E in human prostate carcinoma cell lines. J Urol 2002;168(4 Pt 1):1578-1582.
44. Venkateswaran V, Klotz LH, Fleshner NE. Selenium modulation of cell proliferation and cell cycle biomarkers in human prostate carcinoma cell lines. Cancer Res 2002;62(9):2540-2545.
45. Clark PE, Torti FM. Prostate cancer and bone metastases: Medical treatment. Clin Orthop Relat Res 2003; (415 Suppl): S148-S157.
46. Gilbert SM, McKiernan JM. Epidemiology of male osteoporosis and prostate cancer. Curr Opin Urol 2005;15(1):23-27.
47. Yegen BC. Bombesin-like peptides: Candidates as diagnostic and therapeutic tools. Curr Pharm Des 2003;9(12):1013-1022.
48. Palmer J, Ernst M, Hammacher A, Hertzog PJ. Constitutive activation of gp130 leads to neuroendocrine differentiation in vitro and in vivo. Prostate 2005;62(3):282-289.
49. Cox ME, Deeble PD, Lakhani S, Parsons SJ. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: Implications for prostate cancer progression. Cancer Res 1999;59(15):3821-3830.
50. Konishi N, Shimada K, Ishida E, Nakamura M. Molecular pathology of prostate cancer. Pathol Int 2005;55(9):531-539.
51. Vilches J, Salido M, Fernandez-Segura E, Roomans GM. Neuropeptides, apoptosis and ion changes in prostate cancer. Methods of study and recent developments. Histol Histopathol 2004; 19(3):951-961.
52. Reubi JC, Macke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 2005;46 (Suppl 1):67S-75S.